130 related articles for article (PubMed ID: 16372153)
1. Inhibition of host signal transducer and activator of transcription factor 6 results in cure with cyclophosphamide and interleukin 12 immunotherapy.
Norton JA; Li M; Lee NC; Tsung K
Ann Surg Oncol; 2006 Jan; 13(1):118-24. PubMed ID: 16372153
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
Eggermont AM; Sugarbaker PH
Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
[TBL] [Abstract][Full Text] [Related]
3. Cure of an established nonimmunogenic tumor, SCC VII, with a novel interleukin 12-based immunotherapy regimen in C3H mice.
Mandpe AH; Tsung K; Norton JA
Arch Otolaryngol Head Neck Surg; 2003 Jul; 129(7):786-92. PubMed ID: 12874083
[TBL] [Abstract][Full Text] [Related]
4. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.
Tsung K; Dolan JP; Tsung YL; Norton JA
Cancer Res; 2002 Sep; 62(17):5069-75. PubMed ID: 12208763
[TBL] [Abstract][Full Text] [Related]
5. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12.
Le HN; Lee NC; Tsung K; Norton JA
J Immunol; 2001 Dec; 167(12):6765-72. PubMed ID: 11739491
[TBL] [Abstract][Full Text] [Related]
6. The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target.
Segal JG; Lee NC; Tsung YL; Norton JA; Tsung K
Cancer Res; 2002 Aug; 62(16):4696-703. PubMed ID: 12183428
[TBL] [Abstract][Full Text] [Related]
7. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12.
Tsung K; Meko JB; Tsung YL; Peplinski GR; Norton JA
J Immunol; 1998 Feb; 160(3):1369-77. PubMed ID: 9570556
[TBL] [Abstract][Full Text] [Related]
8. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
Papa MZ; Yang JC; Vetto JT; Shiloni E; Eisenthal A; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):122-9. PubMed ID: 3257159
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
11. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
[TBL] [Abstract][Full Text] [Related]
12. Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy.
Ophir R; Pecht M; Keisari Y; Rashid G; Lourie S; Meshorer A; Ben-Efraim S; Trainin N; Burstein Y
Immunopharmacol Immunotoxicol; 1996 May; 18(2):209-36. PubMed ID: 8771368
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
Kedar E; Chriqui-Zeira E; Kyriazis AP
J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy of murine mammary adenocarcinomas.
Ames IH
Anticancer Res; 2004; 24(4):2249-56. PubMed ID: 15330169
[TBL] [Abstract][Full Text] [Related]
16. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect.
Zhu S; Waguespack M; Barker SA; Li S
Clin Cancer Res; 2007 Jul; 13(14):4252-60. PubMed ID: 17634555
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the expression of adoptive tumor rejection immunity by recipient cyclophosphamide-sensitive cells.
Boyer CM; Kreider JW; Bartlett GL
Cancer Res; 1982 Jun; 42(6):2211-5. PubMed ID: 7042079
[TBL] [Abstract][Full Text] [Related]
19. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
Mokyr MB; Dray S
Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
[TBL] [Abstract][Full Text] [Related]
20. Expression of IL-4 receptor on non-bone marrow-derived cells is necessary for the timely elimination of Strongyloides venezuelensis in mice, but not for intestinal IL-4 production.
Negrão-Corrêa D; Pinho V; Souza DG; Pereira AT; Fernandes A; Scheuermann K; Souza AL; Teixeira MM
Int J Parasitol; 2006 Sep; 36(10-11):1185-95. PubMed ID: 16793046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
